Vaccination with Dendritic Cell Myeloma Fusions in Conjuction with Stem Cell Transplantation and PD-1 Blockade
Technical Report,01 May 2014,30 Apr 2015
Beth Israel Deaconess Medical Center Boston United States
Pagination or Media Count:
In this project, we conducted a clinical trial in which patients with multiple myeloma were treated with an anti-PD1 antibody CT-011 alone Cohort 1 and in conjunction with a dendritic cellmyeloma fusion cell vaccine Cohort 2 following autologous transplantation. The goal ofthe project was to determine the effect of CT-011 alone, and in conjunction with a DCmyeloma fusion cell vaccine, to stimulate effective anti-tumor immunity and disease response.